Aldeyra Therapeutics Inc (ALDX) USD0.001
Sell:$2.66Buy:$2.75
$0.01
(0.38%)
- This stock can be held in a
Stocks and Shares ISA$0.01
(0.38%)$0.01
(0.38%)Company Information
About this company
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Key people
Key facts
- EPICALDX
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS01438T1060
- Market cap$144.49m
- Employees9
- Shares in issue59.71m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.